These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26389941)

  • 21. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis.
    Alves da Silva R; de Souza Todão J; Kamitani FL; Silva AEB; de Carvalho-Filho RJ; Ferraz MLCG; de Carvalho IMVG
    J Med Virol; 2018 Mar; 90(3):537-544. PubMed ID: 29064576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
    Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
    J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan].
    Kartashov MY; Svirin KA; Bekbolotov AA; Momusheva KT; Iskanova BM; Solpueva AS; Motorov UT; Narmatova EB; Krivosheina EI; Gladysheva AV; Chub EV; Gashnikova NM
    Vopr Virusol; 2023 Jul; 68(3):265-270. PubMed ID: 37436417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy.
    Pronier C; Fontaine H; Dorival C; Carrat F; Pol S; Thibault V;
    J Viral Hepat; 2019 Nov; 26(11):1276-1283. PubMed ID: 31273896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
    Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT
    PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.
    Vidal LL; Santos AF; Soares MA
    J Antimicrob Chemother; 2015 Jul; 70(7):2024-7. PubMed ID: 25835991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.